Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage i testicular cancer

BJU International

Volumn 112, Issue 2, 2013, Pages

  Grimison, Peter ^a,b   Houghton, Baerin ^a,b   Chatfield, Mark ^a,b   Toner, Guy C ^a,e,f   Davis, Ian D ^a,g   Martin, Jarad ^a,c   Hovey, Elizabeth ^a,d   Stockler, Martin R ^a,b  

^a Australian and New Zealand Urogenital and Prostate Cancer Trials Group   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

adjuvant chemotherapy; adjuvant radiotherapy; epidemiology; local neoplasm recurrence; mortality; pathology; standards; testicular neoplasms; watchful waiting

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIPLE CYCLE TREATMENT; NAMED GROUPS BY OCCUPATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION EXPOSURE; SEMINOMA; TEAMWORK; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; THORAX RADIOGRAPHY; WATCHFUL WAITING;

AUSTRALIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879617192     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12221     Document Type: Article

References (50)

1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute, 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed November 2011. SEER data submission, posted to the SEER web site, April 2012.
2. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2010: An Overview. Cancer series no. 60. Cat. no. CAN 56., Canberra, ACT: AIHW, 2010
3. Horwich A, Shipley J, Huddart R,. Testicular germ-cell cancer. Lancet 2006; 367: 754-765
4. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23: 1200-1208
5. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999; 17: 1146-1154
6. Mead GM, Fossa SD, Oliver RTD, et al. Randomized Trials in 2466 Patients With Stage I Seminoma: patterns of Relapse and Follow-up. J Natl Cancer Inst 2011; 103: 241-249
7. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20: 4448-4452
8. de Wit R, Fizazi K,. Controversies in the Management of Clinical Stage I Testis Cancer. J Clin Oncol 2006; 24: 5482-5492
9. Chung P, Warde P,. Stage I Seminoma: adjuvant Treatment is Effective but is it Necessary? J Natl Cancer Inst 2011; 103: 194-196
10. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300
11. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128
12. van As NJ, Gilbert DC, Money-Kyrle J, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008; 98: 1894-1902
13. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Testicular Cancer 2012. 2012. NCCN. Available at: http://www.nccn.org. Accessed 18 July 2012
15. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. CUAJ 2010; 4: e19-e38
16. Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer. EAU 2011; Available at: http://www.uroweb.org/professional-resources/guidelines/ online. Accessed 1 January 2013
17. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496
18. Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v147-154
19. Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v140-146
20. Brenner DJ, Hall EJ,. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284
21. Berrington de Gonzalez A, Darby S,. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004; 363: 345-351
22. van Walraven C, Fergusson D, Earle C, et al. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 2011; 29: 2883-2888
23. de Wit R,. Cutting back on computed tomography scan frequency in curative oncology: get the picture. J Clin Oncol 2007; 25: 1308-1309
24. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007; 25: 1310-1315
25. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10: 1762-1768
26. Groll RJ, Warde P, Jewett MA,. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64: 182-197
27. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-4378
28. Huddart R, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523
29. Zagars GK, Ballo MT, Lee AK, Strom SS,. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640
30. Pfanzelter N, Bekelman JE,. Testicular cancer: underestimating radiotherapy toxicity for stage I seminoma. Nat Rev Urol 2012; 9: 241-242
31. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732
32. Travis LB, Fosså SD, Schonfeld SJ, et al. Second Cancers Among 40?576 Testicular Cancer Patients: focus on Long-term Survivors. J Natl Cancer Inst 2005; 97: 1354-1365
33. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T,. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19: 443-447
34. Martin JM, Panzarella T, Zwahlen DR, Chung P, Warde P,. Evidence based guidelines for following stage 1 seminoma. Cancer 2007; 109: 2248-2256
35. Yu HY, Madison RA, Setodji CM, Saigal CS,. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009; 27: 4327-4332
36. Arvold ND, Catalano PJ, Sweeney CJ, et al. Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma. Int J Radiat Oncol Biol Phys 2012; 84: 383-389
37. Tarin TV, Sonn G, Shinghal R,. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181: 627-633
38. Cathomas R, Hartmann M, Krege S, et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011; 34: 59-64
39. Au-Yeung GH, Aly A, Bui A, Vermeltfoort CM, Davis ID,. Uptake of oncology multidisciplinary meeting recommendations. Med J Aust 2012; 196: 36-37
40. Fernandez EB, Colon E, McLeod DG, Moul JW,. Efficacy of radiographic chest imaging in patients with testicular cancer. Urology 1994; 44: 243-248; discussion 8-9
41. Gietema JA, Meinardi MT, Sleijfer DT, Hoekstra HJ, van der Graaf WT,. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002; 13: 1616-1620
42. Harvey ML, Geldart TR, Duell R, Mead GM, Tung K,. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer-a necessary risk? Ann Oncol 2002; 13: 237-242
43. O'Malley ME, Chung P, Haider M, et al. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. Eur Radiol 2010; 20: 1624-1630
44. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002; 42: 553-562; discussion 62-3
45. Hruby G, Choo R, Jackson M, Warde P, Sandler H,. Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia. Australas Radiol 2002; 46: 280-284
46. Kollmannsberger C, Tyldesley S, Moore C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011; 22: 808-814
47. Osswald M, Harlan LC, Penson D, Stevens JL, Clegg LX,. Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol 2009; 27: 604-610
48. Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011; 29: 719-725
49. Vossen CY, Horwich A, Daugaard G, van Poppel H, Osanto S,. Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int 2012; 110: 524-531
50. Chung P, Mayhew LA, Warde P, Winquist E, Lukka H, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based C. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 2010; 22: 6-16